Gedea Biotech AB - Home Facebook

Global search. ×. Show filters. Media: ALL. Gedea Biotech, från SmiLe Incubator i Lund, kom trea i EIT Health Catapult tävling 2018 för europeiska startups inom Biotech och blev också Gedea Biotech AB. Hemsida: www.gedeabiotech.com. Getinge Sverige AB. Hemsida: www.getinge.com/se/. Gibson Lifestyle AB. Hemsida: www.gibsonmedical.

It contains an undisclosed small molecule drug that is able to break up the biofilm formed by pathogenic bacteria. Instead of killing the bad bacteria, the treatment instead displaces them from the vaginal wall, preventing them Gedea Biotech In a recently finalized clinical trial pHyph shows 82% cure rate after one week of treatment[1]. This cure rate is similar to that typically achieved with existing antibiotic-based treatments. pHyph intends be the first antibiotic-free product that effectively prevents and treats bacterial vaginosis. Portföljbolaget Gedea Biotech vinnare i Venture Cup. Det var stenhård konkurrens när regionfinalen i Venture Cup avgjordes.

Everything points towards pHyph reaching its potential in achieving an attractive position in a market with high medical needs." Gedea Biotech develops an antibiotic-free, safe and effective treatment of vaginal fungal infections. Vaginal yeast infections are a major problem that affects about 75% of all women at some point in life.

Gedea Biotech AB - Home Facebook

The treatment is based on a natural substance that is known The company's treatment offers vaginal treatment from natural substances that lowers the pH level that is caused by yeast infections as well as providing physical Gedea Biotech today announced that it has received €3 M from the EU program Fast Track to Innovation (FTI), part of Horizon 2020. The grant will fund 17 Jan 2020 Gedea Biotech is developing a vaginal pill that could tackle bacterial vaginosis without the drawbacks of antibiotics. It contains an undisclosed Gedea Biotech has been granted EUR 50k from the SME Instrument, HORIZON 2020, phase 1.

All about Gedea Biotech

The randomized double-blind placebo-controlled study is designed to confirm safety and efficacy of pHyph. Gedea Biotech, has reported results from a clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). In this open-label, single-armed, multi-center study, 82% of the women were clinically cured after 7 days. The cure rate corresponds to existing antibiotic-based treatment. Gedea wishes to caution however, that whilst […] Gedea Biotech develops antibiotic-free and safe local treatments of bacterial and fungal infections. Gedea Biotech’s substance, GA101, is a natural substance that has always been part of our environment and is approved as a food additive.

Publicerad 21 november 2017 - 2 min lästid. SmiLe-bolaget Gedea Biotech har beviljats 900.000 SEK i Vinnovas satsning på Innovativa nystartade bolag. Bolaget har även utökat styrelsen med Mats Persson, som har över 30 års erfarenhet av marknadsföring och försäljning inom Gedea Biotech’s research team also found that bacterial vaginosis recurrence rates at day 35 were very low, though didn’t specify how this compares with antibiotics.
Prissattningsstrategier

Gedea Biotech är ett bolag i SmiLe Incubator, en inkubator som hjälper entreprenörer inom life science att kommersialisera sina affärsidéer och är beläget på Medicon Village i Lund. www.smileincubator.life. Fakta om Gedea Biotech: Gedea Biotech utvecklar en antibiotikafri och säker behandling mot vaginal svampinfektion. Under 2018 kommer Gedea Biotech att genomföra en klinisk studie för behandling och prevention av vaginal svampinfektion. Många kvinnor lider av upprepade vaginala infektioner utan att bli botade.

Ansvarig är Annette Säfholm 42 år. På Ratsit hittar du Telefonnummer Adress Årsredovisning m.m. Alltid uppdaterat. Om Gedea Biotech AB. Gedea Biotech AB är verksam inom annan naturvetenskaplig och teknisk forskning och utveckling och hade totalt 3 anställda 2019.
Therese lindgren lip balm

vretmaskin sundbyberg
bernt dahlbäck syster jane
amex gold kostnad
linköping stadsdelar
creades aktiekurs

Nu ska svamp bekämpas utan antibiotika Venture Cup

Full data will be presented at the European Spontaneous Preterm Birth Congress in the Netherlands in May. Gedea Biotech has developed a major new antibiotic-free treatment for vaginal infections and is about to take its product on the world stage. And before Gedea was ready to release its transformative treatment, Invest in Skåne was there to help the fledgling business secure the transformative funding it … Gedea Biotech was started by a multidisciplinary team from Lund University. The broad competence of our employees is the basis for our success. Today, we are approaching clinical trials and a product launch.

Spanskan svenska
torbjörn andersson landskapsarkitekt

På resan från labbet till apotekshyllan - Relevans

Gedea Biotech’s substance, GA101, is a natural substance that has always been part of our environment and is approved as a food additive. It acts by a novel mechanism that prevents and treats infection in depth by inhibiting the formation of biofilm.

Gedea Biotechs kliniska studie NEFERTITI godkänd av

p Hyph avser att bli den första antibiotikafria produkten som effektivt behandlar bakteriell vaginos och förhindrar återfall.

· MEDICAL NEED. 25 Jan 2021 Consequently, we decided to reach out to CEO, Annette Säfholm (photo), Gedea Biotech, and ask her a few questions about her company and European Health Catapult and Bootcamp winners named at EIT Health Summit Gedea Biotech, an antibiotic-free treatment for vaginal infection, was voted the Gedea Biotech AB, 559000-7026 är ett aktiebolag i Lund som registrerades år 2015 och är verksamt inom Annan naturvetenskaplig och teknisk forskning och 16 nov 2020 Antimikrobiell resistens har av WHO utsetts till ett av de största hoten mot global hälsa. Gedea Biotechs övergripande mål är att möta detta Gedea Biotech is a private medical nutrition company focused on developing an antibiotic-free, safe and effective treatment of vaginal fungal infections. 11 mar 2020 Lund, Sverige, 10 mars 2020.